Cargando…

Prevalence of hypersexual behavior in Parkinson’s disease patients: Not restricted to males and dopamine agonist use

This study investigates the prevalence and demographic characteristics of hypersexuality in Parkinson’s disease (PD). Impulse control disorders in PD patients have been associated with dopamine agonist therapy. Moreover, hypersexuality and pathological gambling have been associated with males, while...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cooper, Christine A, Jadidian, Armon, Paggi, Michelle, Romrell, Janet, Okun, Michael S, Rodriguez, Ramon L, Fernandez, Hubert H
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2009
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840579/ https://www.ncbi.nlm.nih.gov/pubmed/20360887

Ejemplares similares

Hypersexual Disorder According to the Hypersexual Disorder Screening Inventory in Help-Seeking Swedish Men and Women With Self-Identified Hypersexual Behavior
por: Öberg, Katarina Görts, et al.
Publicado: (2017)

Abstinence from Masturbation and Hypersexuality
por: Zimmer, Felix, et al.
Publicado: (2020)

Testosterone level and the effect of levodopa and agonists in early Parkinson disease: results from the INSPECT cohort
por: Okun, Michael S, et al.
Publicado: (2014)

The role of negative mood states and consequences of hypersexual behaviours in predicting hypersexuality among university students
por: Dhuffar, Manpreet K., et al.
Publicado: (2015)

The treatment of Parkinson's disease with dopamine agonists
por: Konta, Brigitte, et al.
Publicado: (2008)

Inhibitory framing in hypersexual patients with Parkinson’s disease. An fMRI pilot study
por: Theis, Hendrik, et al.
Publicado: (2022)

Impact of behavioral side effects on the management of Parkinson patients treated with dopamine agonists
por: Mohammad, Mohammad Edrees, et al.
Publicado: (2021)

Response inhibition during processing of sexual stimuli in males with problematic hypersexual behavior
por: Seok, Ji-woo, et al.
Publicado: (2020)

Aripiprazol and Hypersexuality: when partial is to much
por: Espada-Santos, P., et al.
Publicado: (2022)

Dopamine Agonist Therapy in Advanced Parkinson’s Disease
por: Reichmann, Heinz
Publicado: (2009)

The four As associated with pathological Parkinson disease gamblers: anxiety, anger, age, and agonists
por: Shapiro, Michael A, et al.
Publicado: (2007)

Two Cases of Hypersexuality Probably Associated with Aripiprazole
por: Cheon, EunJin, et al.
Publicado: (2013)

Subacute sclerosing panencephalitis presenting with hypersexual behavior
por: Manoj, S., et al.
Publicado: (2015)

Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics
por: Blum, Kenneth, et al.
Publicado: (2015)

Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics
por: Blum, Kenneth, et al.
Publicado: (2015)

A case of Klinefelter syndrome with hypersexual desire
por: Okolie, Kingsley, et al.
Publicado: (2017)

Dopamine agonist monotherapy utilization in patients with Parkinson’s disease
por: Frazer, Monica, et al.
Publicado: (2022)

Dopamine Agonists for Pituitary Adenomas
por: Cooper, Odelia, et al.
Publicado: (2018)

Intervention for modifying risk level of hypersexual behaviors among male parents with sexual offending history
por: Egenti, Nkechi T., et al.
Publicado: (2023)

The negative consequences of hypersexuality: Revisiting the factor structure of the Hypersexual Behavior Consequences Scale and its correlates in a large, non-clinical sample
por: Koós, Mónika, et al.
Publicado: (2020)

Naltrexone Use in Treating Hypersexuality Induced by Dopamine Replacement Therapy: Impact of OPRM1 A/G Polymorphism on Its Effectiveness
por: Verholleman, Audrey, et al.
Publicado: (2020)

Correction: Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics
por: Blum, Kenneth, et al.
Publicado: (2015)

Retraction: Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics
por: Blum, Kenneth, et al.
Publicado: (2015)

High Plasma Oxytocin Levels in Men With Hypersexual Disorder
por: Flanagan, John, et al.
Publicado: (2022)

COVID-19-Induced Aggression and Hypersexuality in an Adolescent Patient
por: Parsa, Shyon, et al.
Publicado: (2022)

The Relation of Sexual Attitudes to Hypersexuality and Problematic Pornography Use
por: Lewczuk, Karol, et al.
Publicado: (2022)

The Concept of “Hypersexuality” in the Boundary between Physiological and Pathological Sexuality
por: Perrotta, Giulio
Publicado: (2023)

Causes and factors related to dopamine agonist withdrawal in Parkinson′s disease
por: Castro, Ester Suárez, et al.
Publicado: (2016)

Are Sex Drive and Hypersexuality Associated with Pedophilic Interest and Child Sexual Abuse in a Male Community Sample?
por: Klein, Verena, et al.
Publicado: (2015)

An Eight-Year Clinic Experience with Clozapine Use in a Parkinson’s Disease Clinic Setting
por: Hack, Nawaz, et al.
Publicado: (2014)

A Case of Mania Presenting with Hypersexual Behavior and Gender Dysphoria that Resolved with Valproic Acid
por: Heare, Michelle R., et al.
Publicado: (2016)

Hypersexual Behavior Following Craniocerebral Trauma An Experience with Five Cases
por: Eghwrudjakpor, PO, et al.
Publicado: (2008)

A Treatment-Oriented Typology of Self-Identified Hypersexuality Referrals
por: Cantor, James M., et al.
Publicado: (2013)

Neural Substrates of Sexual Desire in Individuals with Problematic Hypersexual Behavior
por: Seok, Ji-Woo, et al.
Publicado: (2015)

Modafinil Dependence and Hypersexuality: A Case Report and Review of the Evidence
por: Swapnajeet, Sahoo, et al.
Publicado: (2016)

A Case of Hypersexuality in a Patient Receiving Aripiprazole for Schizophrenia
por: Priya, Lakshmi, et al.
Publicado: (2021)

Correction: Are Sex Drive and Hypersexuality Associated with Pedophilic Interest and Child Sexual Abuse in a Male Community Sample?
Publicado: (2015)

Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist
por: Zhang, Jinglin, et al.
Publicado: (2016)

Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease
por: Picillo, Marina, et al.
Publicado: (2020)

Dopamine Agonist-Associated Hiccup in Parkinson’s Disease: A Case Report
por: EMEKLİ, Ahmed Serkan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ut5muscn9uotbpc2o33dq2me0c